Adjunct Faculty
Adjunct faculty typically have an academic or research appointment at another institution and contribute or collaborate with one or more School of Medicine faculty members or programs.
Adjunct rank detailsLaura Niklason, PhD, MD
Professor AdjunctDownloadHi-Res Photo
About
Copy Link
Titles
Professor Adjunct
Division Chief; Vice Chair, Research
Biography
Dr. Niklason is the Nicholas M. Greene Professor at Yale University in Anesthesia and Biomedical Engineering, where she has been on faculty since 2006. Dr. Niklason’s research focuses primarily on regenerative strategies for cardiovascular and lung tissues. Niklason’s engineered blood vessels are currently in clinical trials, and are the first life-sustaining engineered tissue to be studied in any Phase III trial. Niklason’s lab was also one of the first to describe the engineering of whole lung tissue that could exchange gas in vivo, and this work was cited in 2010 as one of the top 50 most important inventions of the year by Time Magazine. She was inducted into the National Academy of Inventors in 2014, and was elected to the National Academy of Medicine in 2015.
Niklason received her PhD in Biophysics from the University of Chicago, and her MD from the University of Michigan. She completed her residency training in anesthesia and intensive care unit medicine at the Massachusetts General Hospital in Boston, and completed post-doctoral scientific training at Massachusetts Institute of Technology.
Last Updated on April 07, 2025.
Appointments
Anesthesiology
Professor AdjunctPrimary
Other Departments & Organizations
- Anesthesiology
- NIH T32 Program
- Niklason Lab
- Yale Stem Cell Center
- Yale Ventures
Education & Training
- Fellow
- Mass General Hospital (1996)
- Resident
- Mass General Hospital (1995)
- Intern
- University of Michigan (1992)
- MD
- University of Michigan/Ann Arbor (1991)
- PhD
- University of Chicago (1988)
Research
Copy Link
Overview
Currently, Dr. Niklason's research program has several areas of focus. With regard to engineered arteries. Niklason is engaged in preclinical studies in large animals to validate the method for generating engineered tissues that are available "off the shelf". Large animal studies on vascular grafts are centered on immune/inflammatory response minimization to these off-the-shelf tissues, and on the long-term function of the grafts in the arterial circulation. In addition, Niklason is developing tissue engineering approaches to generating vascularized cardiac muscle, as well as vascularized lung tissue. In addition, Niklason has active research interests in vascular remodeling that is associated with various disease states, including atherosclerosis and arterial vaso spasm.
- Tissue engineered arteries, utilizing decellularization approaches
- Regeneration of whole, functional lung tissue
- Engineering of thoracic conduits, including trachea and esophagus
- Investigation of the molecular basis of cellular aging in various tissues
- Investigation of causes of intimal hyperplasia in vein grafts
Medical Research Interests
Anesthesiology; Biomedical Engineering; Biophysics; Blood Vessels; Lung; Physics; Tissue Engineering
ORCID
0000-0002-5156-504X
Research at a Glance
Yale Co-Authors
Frequent collaborators of Laura Niklason's published research.
Publications Timeline
A big-picture view of Laura Niklason's research output by year.
Research Interests
Research topics Laura Niklason is interested in exploring.
Micha Sam Brickman Raredon, MD, PhD
Liping Zhao, MS, HT (ASCP)
Naftali Kaminski, MD
Yifan Yuan
Dianqing (Dan) Wu, PhD
Farida Ahangari, MD
40Publications
3,270Citations
Tissue Engineering
Lung
Blood Vessels
Publications
2025
Long-term safety and efficacy outcomes of the Acellular Tissue Engineered Vessel (ATEV) in extremity arterial trauma repair
Curi M, Moore E, Namias N, Kundi R, Lum Y, Fox C, Goldin I, Bou-Ghannam S, Berdugo M, Khondker Z, Parikh S, Niklason L. Long-term safety and efficacy outcomes of the Acellular Tissue Engineered Vessel (ATEV) in extremity arterial trauma repair. Journal Of Vascular Surgery Cases And Innovative Techniques 2025, 12: 102042. PMID: 41438419, PMCID: PMC12720075, DOI: 10.1016/j.jvscit.2025.102042.Peer-Reviewed Original ResearchConceptsLong-term safetyAdverse eventsLimb salvageArterial injuryVascular injuryHigh-risk trauma populationArterial reconstructionSaphenous veinAutologous veinInfection-free rateCases of arterial injuryImmune-mediated rejectionKaplan-Meier methodSerious adverse eventsAssociated with lower infection ratesInfection rateLong-term patencyLimb salvage outcomesMechanism of injuryExtremity vascular injuriesSecondary patencyPrimary patencyPatient yearsEfficacy outcomesPatient survivalShort-term performance of Symvess (acellular tissue engineered vessel-tyod) compared to external control data for autologous vein in treatment of extremity arterial injury
Rajani R, Velez F, Knight T, Kauffman L, Pascarella L, Malone D, Rasmussen T, Niklason L, Parikh S. Short-term performance of Symvess (acellular tissue engineered vessel-tyod) compared to external control data for autologous vein in treatment of extremity arterial injury. Trauma Surgery & Acute Care Open 2025, 10: e001814. PMID: 41180255, PMCID: PMC12574343, DOI: 10.1136/tsaco-2025-001814.Peer-Reviewed Original ResearchCitationsAltmetricConceptsExtremity arterial injuriesShort-term clinical performanceInjury Severity ScoreAutologous groupSeverity scoreArterial injuryAutologous veinMangled Extremity Severity ScoreDuration of follow-upHuman acellular vesselShort-term outcomesCase of pseudoaneurysmIncidence of outcomesShunt useRegistry subjectsSecondary patencyPrimary patencyConduit infectionTherapeutic/care managementConcomitant fracturesPosterior tibial arteryAcellular vesselsFollow-upInitial hospitalizationClinical trialsTwo-Year Outcomes from a Prospective Randomized Trial of Humacyte's Acellular Tissue Engineered Vessel vs. Autologous Arteriovenous Fistula for Hemodialysis Access
Hussain M, Moore E, Khondker Z, Parikh S, Niklason L. Two-Year Outcomes from a Prospective Randomized Trial of Humacyte's Acellular Tissue Engineered Vessel vs. Autologous Arteriovenous Fistula for Hemodialysis Access. Journal Of The American Society Of Nephrology 2025, 36: 10.1681/asn.2025s5e9mg2y. DOI: 10.1681/asn.2025s5e9mg2y.Peer-Reviewed Original ResearchAcellular Tissue Engineered Vessels as Coronary Artery Bypass Grafts
Williams A, Nash K, Kirkton R, Levitan G, Daubert M, Whitney S, Naegeli K, Benkert A, McCartney S, Prichard H, Niklason L, Kypson A. Acellular Tissue Engineered Vessels as Coronary Artery Bypass Grafts. JACC Basic To Translational Science 2025, 10: 101379. PMID: 40939573, PMCID: PMC12665417, DOI: 10.1016/j.jacbts.2025.101379.Peer-Reviewed Original ResearchCitationsAltmetricConceptsCoronary Artery Bypass GraftingRight coronary arteryComputed tomography angiographyArtery Bypass GraftingBypass GraftingCoronary arteryInternal mammary arterySmooth muscle cellsTissue engineered vesselTissue-engineered vesselsCoronary artery bypass grafting conduitsCardiac functionHost cell ingrowthMammary arteryMuscle cellsSaphenous veinPrimate modelCell ingrowthArteryAdult baboonsAngiographyGene expression patternsGraftExpression patternsBioengineered human blood vessels to treat hospital-acquired vascular complications
Lum Y, Moore E, Kundi R, Morrison J, Shores J, Niklason L, Parikh S. Bioengineered human blood vessels to treat hospital-acquired vascular complications. Journal Of Vascular Surgery Cases And Innovative Techniques 2025, 11: 101976. PMID: 41140335, PMCID: PMC12547166, DOI: 10.1016/j.jvscit.2025.101976.Peer-Reviewed Original ResearchAltmetricConceptsFollow-upIatrogenic injuryVascular proceduresRepair of arterial injuriesComplication of vascular surgeryAutologous veinPatent conduitOncologic tumor resectionSingle-arm clinical trialLimb salvageLevel I trauma centerArteriovenous access placementCompleteness of follow-upAverage follow-upVascular surgical proceduresMean lengthComplications of vascular proceduresHuman vascular cellsSecondary patencyTumor resectionPrimary patencyConduit infectionUrgent/emergent settingsPatient survivalSteal syndromeAcellular Tissue Engineered Vessel Outperforms Arteriovenous Fistula in High-Risk Patients on Hemodialysis: Results From the CLN-PRO-V007 Randomized Controlled Trial
Hussain M, Ozaki C, Moore E, Khondker Z, Parikh S, Niklason L. Acellular Tissue Engineered Vessel Outperforms Arteriovenous Fistula in High-Risk Patients on Hemodialysis: Results From the CLN-PRO-V007 Randomized Controlled Trial. Journal Of Vascular Surgery 2025, 81: e309-e310. DOI: 10.1016/j.jvs.2025.03.456.Peer-Reviewed Original ResearchCitationsAltmetricAdrenomedullin Is Enriched in Human Lung Vascular Niche and Enhances Endothelial Cell Maturation in Bioengineered Lung Models
Yoon Y, Kirk S, Raredon M, Kaminski N, Niklason L, Yuan Y. Adrenomedullin Is Enriched in Human Lung Vascular Niche and Enhances Endothelial Cell Maturation in Bioengineered Lung Models. American Journal Of Respiratory And Critical Care Medicine 2025, 211: a7243-a7243. DOI: 10.1164/ajrccm.2025.211.abstracts.a7243.Peer-Reviewed Original ResearchBudget impact model of acellular tissue engineered vessel for the repair of extremity arterial trauma when autologous vein is not feasible
Velez F, Rajani R, Malone D, Sun L, Bloudek L, Carter K, Panaccio M, Niklason L. Budget impact model of acellular tissue engineered vessel for the repair of extremity arterial trauma when autologous vein is not feasible. Journal Of Medical Economics 2025, 28: 323-334. PMID: 39964834, DOI: 10.1080/13696998.2025.2469460.Peer-Reviewed Original ResearchAltmetricMeSH Keywords and ConceptsConceptsConduit infectionAutologous veinTissue engineered vesselHarvest site infectionBudget impactTrauma centerSurgical re-interventionOperating roomLevel I trauma centerGraft infectionBudget impact modelRe-interventionComplication rateSite infectionVein repairGraft typeClinical studiesProsthetic graftsParameter uncertaintiesPost-discharge costsArterial traumaPROOVIT registryTrauma repairOR timeInfection
2024
Prospective Randomized Trial of Humacyte's Acellular Tissue Engineered Vessel vs. Autologous Arteriovenous Fistula for Hemodialysis Access
Hussain M, Ozaki C, Moore E, Khondker Z, Parikh S, Niklason L. Prospective Randomized Trial of Humacyte's Acellular Tissue Engineered Vessel vs. Autologous Arteriovenous Fistula for Hemodialysis Access. Journal Of The American Society Of Nephrology 2024, 35: 10.1681/asn.2024y8139maa. DOI: 10.1681/asn.2024y8139maa.Peer-Reviewed Original ResearchEngineered vascular grafts lend unique insight to pathophysiology of aortic aneurysms
Naegeli K, Niklason L. Engineered vascular grafts lend unique insight to pathophysiology of aortic aneurysms. Cell Stem Cell 2024, 31: 1099-1100. PMID: 39094540, DOI: 10.1016/j.stem.2024.07.002.Peer-Reviewed Original ResearchCitationsMeSH Keywords and Concepts
Academic Achievements & Community Involvement
Copy Link
Activities
activity Stem Cell Research
01/01/2007 - PresentResearchDetailsUnited KingdomAbstract/SynopsisProfessor Niklason collaborates with Dr. Sanjay Sinha and Dr. Roger Pedersen of Cambridge University. Their work centers on stem cell research.
Get In Touch
Copy Link